DaVita Inc. DVA
Analyst Ratings
- Consensus
- Moderate Buy — 3 Buy · 2 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $229.80 (+31.1% upside)
Key Stats
- Today's Range
- $171.09 – $191.20
- 50-Day Range
- $171.09 – $195.75
- 52-Week Range
- $101.00 – $247.49
- Volume
- 2.07 million shs
- Average Volume
- 687K shs
- Market Cap
- $11.19 billion
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 6.99%
- Days to Cover
- 3.83
About DaVita Inc.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Related Stocks
Compare head-to-head: DVA vs AGL·DVA vs VMD·DVA vs CCEL
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.